Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use WAYRILZ™ safely and effectively. See full prescribing information for WAYRILZ. WAYRILZ™ (rilzabrutinib) tablets, for oral use Initial U.S. Approval: 2025
Medication labelWhy this: Advisory · dailymed-prescription
WAYRILZ is indicated for the treatment of adult patients with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
- generic_name
- rilzabrutinib
- product_names
- rilzabrutinib
- ndc
- 58468-0251, 58468-0251-6, 58468-0251-0, 58468-0251-5
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en